The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts - PubMed (original) (raw)
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts
V Fremeaux-Bacchi et al. J Med Genet. 2005 Nov.
Abstract
Background: In both familial and sporadic atypical haemolytic-uraemic syndrome (aHUS), mutations have been reported in regulators of the alternative complement pathway including factor H (CFH), membrane cofactor protein (MCP), and the serine protease factor I (IF). A characteristic feature of both MCP and CFH associated HUS is reduced penetrance and variable inheritance; one possible explanation for this is that functional changes in complement proteins act as modifiers.
Objective: To examine single nucleotide polymorphisms in both CFH and MCP genes in two large cohorts of HUS patients (Newcastle and Paris).
Results: In both cohorts there was an association with HUS for both CFH and MCP alleles. CFH and MCP haplotypes were also significantly different in HUS patients compared with controls.
Conclusions: This study suggests that there are naturally occurring susceptibility factors in CFH and MCP for the development of atypical HUS.
Similar articles
- Atypical haemolytic uraemic syndrome.
Kavanagh D, Goodship TH, Richards A. Kavanagh D, et al. Br Med Bull. 2006;77-78:5-22. doi: 10.1093/bmb/ldl004. Epub 2006 Sep 11. Br Med Bull. 2006. PMID: 16968692 Review. - Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C; French Society of Pediatric Nephrology. Sellier-Leclerc AL, et al. J Am Soc Nephrol. 2007 Aug;18(8):2392-400. doi: 10.1681/ASN.2006080811. Epub 2007 Jun 28. J Am Soc Nephrol. 2007. PMID: 17599974 - The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, Hourcade DE, Atkinson JP, Goodship TH. Kavanagh D, et al. Mol Immunol. 2007 May;44(12):3162-7. doi: 10.1016/j.molimm.2007.01.036. Epub 2007 Mar 21. Mol Immunol. 2007. PMID: 17368771 - The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. Saunders RE, et al. Hum Mutat. 2007 Mar;28(3):222-34. doi: 10.1002/humu.20435. Hum Mutat. 2007. PMID: 17089378 - Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. Richards A, et al. Mol Immunol. 2007 Jan;44(1-3):111-22. doi: 10.1016/j.molimm.2006.07.004. Epub 2006 Aug 1. Mol Immunol. 2007. PMID: 16882452 Review.
Cited by
- Anti-factor H antibody and its role in atypical hemolytic uremic syndrome.
Raina R, Mangat G, Hong G, Shah R, Nair N, Abboud B, Bagga S, Sethi SK. Raina R, et al. Front Immunol. 2022 Aug 23;13:931210. doi: 10.3389/fimmu.2022.931210. eCollection 2022. Front Immunol. 2022. PMID: 36091034 Free PMC article. - Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.
Ermini L, Goodship TH, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS. Ermini L, et al. Mol Immunol. 2012 Jan;49(4):640-8. doi: 10.1016/j.molimm.2011.11.003. Epub 2011 Dec 5. Mol Immunol. 2012. PMID: 22153652 Free PMC article. - Thrombotic microangiopathy and intravenous immunoglobulin therapy.
Watanabe T. Watanabe T. Pediatr Nephrol. 2007 Jun;22(6):907-8; author reply 909. doi: 10.1007/s00467-007-0441-2. Epub 2007 Feb 13. Pediatr Nephrol. 2007. PMID: 17295029 No abstract available. - Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus.
Jönsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG, Bengtsson A, Zickert A, Eloranta ML, Truedsson L, Rönnblom L, Nordmark G, Sturfelt G, Blom AM. Jönsen A, et al. Arthritis Res Ther. 2011;13(6):R206. doi: 10.1186/ar3539. Epub 2011 Dec 15. Arthritis Res Ther. 2011. PMID: 22171659 Free PMC article. - Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.
Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Caprioli J, et al. Blood. 2006 Aug 15;108(4):1267-79. doi: 10.1182/blood-2005-10-007252. Epub 2006 Apr 18. Blood. 2006. PMID: 16621965 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous